Loading...

Halozyme Therapeutics, Inc.

HALONASDAQ
Healthcare
Biotechnology
$53.96
$1.94(3.73%)

Halozyme Therapeutics, Inc. HALO Peers

See (HALO) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
HALO$53.96+3.73%6.5B14.07$3.76N/A
VRTX$455.58+2.33%116.1B-117.75-$3.84N/A
REGN$548.63+4.50%56.8B13.59$39.35+0.16%
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ALNY$325.30-0.24%42B-152.64-$2.11N/A
ARGX$547.03-0.76%33.1B33.10$16.39N/A
BNTX$107.98+1.42%25.8B-29.37-$3.66N/A
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
RPRX$36.04+0.03%20.2B14.64$2.45+2.40%
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HALO vs VRTX Comparison

HALO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HALO stands at 6.5B. In comparison, VRTX has a market cap of 116.1B. Regarding current trading prices, HALO is priced at $53.96, while VRTX trades at $455.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HALO currently has a P/E ratio of 14.07, whereas VRTX's P/E ratio is -117.75. In terms of profitability, HALO's ROE is +1.22%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, HALO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for HALO.

Stock Price Comparison

Loading...

Frequently Asked Questions

;